Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Recurrence

Urinary Bladder Neoplasms

Prostatic Hyperplasia

Hyperplasia

Disease Progression

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Male Urogenital Diseases

Urological Agents

All Drugs and Chemicals

Tamsulosin

Adrenergic alpha-Antagonists

Adrenergic Agents

Adrenergic alpha-1 Receptor Antagonists

Adrenergic Antagonists

Neurotransmitter Agents

Patients taken tamsulosin for benign prostate hyperplasia who have non muscle invasive bladder cancer

Patients taken transurethral resection prostatectomy for benign prostate hyperplasia who have non muscle invasive bladder cancer

Transurethral Resection

Medical treatment for benign prostate hyperplasia

Nihat Karakoyunlu, MD

The purpose of this study is to compare medical and surgical treatments of benign prostate hyperplasia in patients who have non muscle invasive bladder cancer for tumour recurrence and progression.

Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression

Diskapi Teaching and Research Hospital

Digestive System Diseases

Rare Diseases

Urinary Retention

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Rectal Diseases

Urination Disorders

Acute Graft Versus Host Disease

Sung-Bum Kang, M.D., Ph.D

Various adrenergic blockers are used for acute voiding difficulty after proctectomy. Recently, a selective alpha5-adrenergic blocker, Tamsulosin has been reported to have benefit in reducing urinary symptom score and in reducing the rate of intermittent self-catheterization for patients with rectal cancer after radical proctectomy.

This study is to evaluate the efficacy of pharmacologic prevention to ameliorate the incidence of postoperative urinary dysfunction.

Acute voiding difficulty is caused from damage to pelvic sympathetic nerve after rectal surgery, and usually resolved spontaneously within several months after the surgery. However, acute voiding difficulty results in prolonged insertion of urinary catheter and is associated risk for urinary tract infection. Various adrenergic blockers are used for acute voiding difficulty after proctectomy. Recently, a selective alpha5-adrenergic blocker, Tamsulosin has been reported to have benefit in reducing urinary symptom score and in reducing the rate of intermittent self-catheterization for patients with rectal cancer after radical proctectomy.

This study is to evaluate the efficacy of pharmacologic prevention to ameliorate teh incidence of postoperative urinary dysfunction.

Prevention of Acute Voiding Difficulty After Radical Proctectomy

Prevention of Acute Voiding Difficulty After Radical Proctectomy for Rectal Cancer With Tamsulosin

Seoul National University Hospital

Sung-Bum Kang

Prostatic Neoplasms

Hypertrophy

Lower Urinary Tract Symptoms

Prostatic Diseases

Pathological Conditions, Anatomical

Genital Neoplasms, Male

Genital Diseases

Genital Diseases, Male

Single dose tamsulosin 0.4mg

Double dose tamsulosin 0.4mg

Single dose versus double dose tamsulosin in Management of Moderate and severe lower urinary tract symptoms due to benign prostatic hyperplasia

Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH

Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Assessed by the improvement in the internal prostatic symptoms score (IPSS)

Menoufia University

Anti-Inflammatory Agents

Antineoplastic Agents

Antiemetics

Gastrointestinal Agents

Dexamethasone

Dexamethasone acetate

BB 1101

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days

single fraction IGRT at a prescription dose of 24 Gy

Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation

IGRT 45 Gy in 5 fractions of 9 Gy

Administration of a single dose of 24 Gy in one session

IGRT 24 Gy single dose

0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.

Madhur Garg, MD

The present study evaluates clinical outcomes and treatment-related toxicity following definitive ultra-high dose external beam radiotherapy delivered with two different regimens in patients with intermediate-risk adenocarcinoma of the prostate. Modern computer-driven technology enables the implementation of ultra-high hypofractionated Image-Guided Radiotherapy (IGRT) safely.

Prostate cancer patients classified according to the current National Comprehensive Cancer Network (NCCN) guidelines as intermediate risk (biopsy Gleason score of 7 and/or Prostate Specific Antigen (PSA) level \>10 and ≤20 ng/mL and/or Stage T1, T2a, T2b or T2c) are eligible for this study.

Patients will undergo IGRT with volumetric intensity-modulated arc radiotherapy (VMAT) with state-of-the-art treatment-planning and quality assurance procedures. Emphasis is placed on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility, while a urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking. Previously untreated patients with intermediate-risk prostate cancer will be prospectively randomized to receive either 45 Gy in five fractions of 9 Gy each vs. 24 Gy in a single-dose.

Patients will be followed at one month post-treatment and every 3 months for up to 12 months (+/- 4 weeks) and every 6 months thereafter. Acute and chronic toxicity evaluations will focus on urinary, rectal and sexual functions and will be assessed through validated questionnaires. Serum PSA values will be regularly acquired during follow-up. A multiparametric MRI will be performed at baseline, 6, 12 and 24 months following intervention. Additionally, a post-treatment diffusion-weighted MRI (DW-MRI) will be performed within 15 minutes of the first treatment, to measure early physiologic changes, such as perfusion and ischemia, that may correlate with clinically relevant end-points. Post-treatment prostate needle biopsies will be obtained at 24 months to evaluate pathologic response to therapy. The study will be continuously monitored for a minimum of 5 years. In the event unexpected severe (grade ≥3) toxicities are observed in any one of the treatment arms, the study will be terminated according to the stopping rule \>3/first 15 patients.

This is open label feasibility study where patients enrolled in the study will undergo image-guided, intensity-modulated radiotherapy using the same equipment, techniques, and treatment-planning procedures as currently practiced at CCU. Eligible patients will receive either 45 Gy in 5 sessions each of 9 Gy delivered in one week (arm A) or 24 Gy in 1 session (arm B) to assess the dose limiting toxicities in the two groups. Patients will be randomized to arm A or arm B.

Dose limiting toxicity (DLT) is defined as any Grade 3 urinary or rectal toxicity, based on NCI CTCAE v4.0, observed within 3 months of completion of protocol radiation. If, at any point in the conduct of the trial, DLTs are observed in three patients in a study arm, accrual to that arm will be terminated.

There are three aspects of this study that will be different from the currently used standard treatment for definitive external beam treatment of prostate cancer:

1. The dose-fractionation scheme, as per the treatment arm.
2. Acquisition of a set of prostate biopsies at 24 months post treatment
3. Examination of imaging response based on multi-parametric MRI

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer

Comparison of treatment related adverse events as measured by Common Toxicity Criteria for Adverse Effects v4.0 over a 5 year time frame

The International Prostate Symptom Score (IPSS) can be utilized to measure the severity of lower urinary tract symptoms.The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.

Albert Einstein College of Medicine

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression	NCT02443844	Bladder Cancer	Transurethral R... Tamsulosin	40 Years - 80 Years	Diskapi Teaching and Research Hospital
Prevention of Acute Voiding Difficulty After Radical Proctectomy	NCT00606983	Rectal Cancer Urinary Retenti...	Tamsulosin	20 Years - 80 Years	Seoul National University Hospital
Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH	NCT05834270	Prostatic Neopl... Prostate Diseas... Prostate Obstru... Prostate Hypert...	Single dose tam... Double dose tam...	50 Years - 80 Years	Menoufia University
A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer	NCT04147806	Prostate Cancer	IGRT 45 Gy in 5... IGRT 24 Gy sing... Dexamethasone Tamsulosin	50 Years -	Albert Einstein College of Medicine
A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer	NCT04147806	Prostate Cancer	IGRT 45 Gy in 5... IGRT 24 Gy sing... Dexamethasone Tamsulosin	50 Years -	Albert Einstein College of Medicine
Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH	NCT05834270	Prostatic Neopl... Prostate Diseas... Prostate Obstru... Prostate Hypert...	Single dose tam... Double dose tam...	50 Years - 80 Years	Menoufia University
Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH	NCT05834270	Prostatic Neopl... Prostate Diseas... Prostate Obstru... Prostate Hypert...	Single dose tam... Double dose tam...	50 Years - 80 Years	Menoufia University
Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression	NCT02443844	Bladder Cancer	Transurethral R... Tamsulosin	40 Years - 80 Years	Diskapi Teaching and Research Hospital

Spots Global Cancer Trial Database for tamsulosin

Every month we try and update this database with for tamsulosin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for tamsulosin

Every month we try and update this database with for tamsulosin cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for tamsulosin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.